Sage Therapeutics is a brand that is revolutionizing the treatment of brain health disorders. With a focus on developing novel drug candidates, they are dedicated to transforming the lives of individuals affected by these conditions. Their industry-leading pipeline includes the first and only product approved in the United States for women with postpartum depression, as well as five new chemical entity clinical candidates across nine indications.

Sage Therapeutics places a strong emphasis on the modulation of GABA and NMDA receptors, which are critical neurotransmitter systems in the brain. Dysfunction in these systems has been linked to numerous depressive, neurological, and neuropsychiatric disorders. By designing compounds that restore the delicate balance of excitatory and inhibitory signals in the brain, Sage Therapeutics aims to treat a range of cognitive, neurological, and behavioral symptoms associated with brain health disorders.

Through their translational approach, Sage Therapeutics selects compounds based on their activity in pre-clinical models of brain function. They also employ functional biomarkers and translational experiments to inform the design of clinical trials and identify patient populations that may benefit from their innovative therapies. With a strong dedication to research and development, Sage Therapeutics is paving the way for new and effective treatments for brain health disorders